Actively Recruiting
Evaluating ALN-AGT01 RVR Versus Placebo Following Zilebesiran in Adults with Mild to Moderate Hypertension A Randomized, Double-Blind Study
Led by Alnylam Pharmaceuticals · Updated on 2026-10-08
93
Participants Needed
3
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness, pharmacodynamics, and safety of ALN-AGT01 RVR in adults with mild to moderate hypertension who have been pretreated with zilebesiran. The study is a phase 2, randomized, double-blind, placebo-controlled trial designed to assess how ALN-AGT01 RVR works following a single dose of zilebesiran. The study is conducted in two parts. Part A involves a single dose, dose-ranging phase for adults with mild to moderate hypertension, while Part B involves a single dose phase in a similar population. Participants receive a single dose of zilebesiran followed by either a single dose of ALN-AGT01 RVR or a placebo, both administered subcutaneously. Participants will be monitored for blood pressure changes, serum angiotensinogen levels, and adverse events over several days and months. The primary outcomes include the percentage recovery from baseline in serum angiotensinogen and mean seated office systolic blood pressure at specified days. Safety is assessed by tracking adverse events for up to 10 months, and participant involvement includes visits for dosing and follow-up assessments throughout the study duration.
CONDITIONS
Brief Title
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
Research Team
A
Alnylam Clinical Trial Information Line
A
Alnylam Clinical Trial Information Line
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here